9 Quotes by Kevin Sharer

We remain confident in our long-term guidance of compound annual growth rate for sales and EPS of low 20s for the 2001-2005 period and sales between $8 billion and $9 billion in 2005,

I think Amgen will be a multi-therapeutic company.

We are balancing the need for continued investment to ensure the success of these new products while at the same time delivering continued earnings growth.

We need to have full tests to protect patient safety.

We are delighted with the inaugural Amgen Tour of California. We are also pleased with the success of our Breakaway from Cancer initiative, which resulted in a donation of $1.1 million to The Wellness Community to support cancer patients. Amgen looks forward to our continuing sponsorship of this world class cycling event.

Breakaway from Cancer is an integral, complementary component of the Amgen Tour of California, and it benefits cancer patients across the country. Amgen was proud to host the Breakaway from Cancer charity ride in our headquarters city and join members of the community to raise additional funds to help empower people with cancer so they can live well with the disease.

It's not like pills, where almost overnight you can lose 98% market share. That's not going to happen, because these are much more complicated drugs to manufacture.

It'll have an effect on Amgen, for sure, but it's just hard to predict what.

Amgen is growing rapidly, and our scale and complexity require that we have one executive be responsible for research and development, ... In addition, we plan multiple global product launches, and we need one executive to integrate our worldwide sales and marketing activities.